BAM 15

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

BAM 15 是线粒体质子载体的解偶联剂。在寡霉素存在的情况下，BAM 15 完全能够增加线粒体呼吸，并且在成肌细胞和肝细胞中的浓度范围比 FCCP 更宽，并且能够在宽剂量范围内增加 O2 消耗，而不增加 ROS。

BAM 15 is an uncoupler of mitochondrial protonophore. BAM 15 is fully capable of increasing mitochondrial respiration in the presence of oligomycin and does so across a broader concentration range than FCCP in both myoblasts and hepatocytes and it is able to increase O2 consumption across a broad dosing range without increasing ROS. BAM 15 and FCCP are structurally unrelated. Which is observed that low doses of BAM 15 from 100 nM to 1 μM increase cellular O2 consumption rate (OCR) to a similar degree as FCCP, However higher concentrations from 1 μM to 50 μM reveal that BAM 15 is able to maintain uncoupled respiration at a high rate in a range of cell lines. BAM 15 induces mitochondrial swelling, demonstrating that BAM 15 is a protonophore. BAM15-treated cells are more viable than FCCP-treated cells when administered across a broad dosing range up to 50 μM.Compare to vehicle-treated mice, animals that receive BAM 15 are protected from kidney injury as indicated by lower plasma creatinine levels at 24 and 48 h post-ischemia, reduced tubular necrosis, less obstruction of proximal tubules, less depletion of brush border villi, and less immune cell infiltration.

BAM 15 is able to increase O2 consumption across a broad dosing range without increasing ROS. BAM 15 and FCCP are structurally unrelated and it is observed that low doses of BAM 15 from 100 nM to 1 μM increase cellular O2 consumption rate (OCR) to a similar degree as FCCP, but higher concentrations from 1 μM to 50 μM reveal that BAM 15 is able to maintain uncoupled respiration at a high rate in a range of cell lines. BAM 15 is fully capable of increasing mitochondrial respiration in the presence of oligomycin and does so across a broader concentration range than FCCP in both myoblasts and hepatocytes.BAM 15 induces mitochondrial swelling, demonstrating that BAM 15 is a protonophore. BAM15-treated cells are more viable than FCCP-treated cells when administered across a broad dosing range up to 50 μM.

Compare to vehicle-treated mice, animals that receive BAM 15 are protected from kidney injury as indicated by lower plasma creatinine levels at 24 and 48 h post-ischemia, reduced tubular necrosis, less depletion of brush border villi, less obstruction of proximal tubules, and less immune cell infiltration.

——

Others

Other Targets

oxidative phosphorylation (OXPHOS)

——

——

210302-17-3

340.29

C16H10F2N6O

>98% (HPLC)

DMSO:72 mg/mL (211.58mM; Need ultrasonic)

Fc1ccccc1Nc1nc2nonc2nc1Nc1ccccc1F

——

(-20℃)

With Ice Pack

≥ 2 years